Clinical experience with the use of combination drug therapy in the first line treatment of metastatic non-small cell lung cancer
- Autores: Ivanova F.G.1,2, Nikolaeva T.I.1, Spiridonova N.I.1, Afanasyeva L.N.2, Nikiforov P.V.2,3, Zharnikova T.N.1,2
-
Afiliações:
- Yakut Republican Oncology Dispensary
- M.K. Ammosov North-Eastern Federal University
- Yakut Republican Medical Information and Analytical Center
- Edição: Volume 30, Nº 14 (2023)
- Páginas: 138-142
- Seção: Oncology
- URL: https://journals.eco-vector.com/2073-4034/article/view/626268
- DOI: https://doi.org/10.18565/pharmateca.2023.14.138-142
- ID: 626268
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
Background. Lung cancer occupies a leading place in the structure of morbidity and mortality from cancer in Russia and in the world. Non-small cell lung cancer (NSCLC) accounts for about 85% of cases among all lung malignancies; 42.2% of lung cancer cases in Russia were detected at the most advanced stage IV. Today, the optimal first-line treatment for patients with stage IV NSCLC without driver mutations, regardless of the level of PD-L1 expression, includes combination treatment regimens, representing by various combinations of chemotherapy, immune checkpoint inhibitors, and antiangiogenic therapy for the non-squamous histotype.
Description of a clinical case. A patient born in 1965 was under medical supervision with peripheral cancer of the upper lobe of the right lung, T1N0M0, stage I at the time of diagnosis, with relapse in the form of metastases in the supraclavicular, subclavian and bronchopulmonary lymph nodes 5 years after the atypical resection and subsequent rethoracotomy with upper lobectomy. Tumor control in the form of complete regression of lesions after three courses of combination therapy using an immune checkpoint inhibitor, cytotoxic drugs and an angiogenesis inhibitor with progression-free survival of more than a year was achieved. Tolerability of treatment was satisfactory.
Conclusion. The use of a combination with atezolizumab in patients with EGFR and ALK negative stage IV NSCLC who have not previously received therapy for advanced disease can significantly improve patient survival.
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
Feodosia Ivanova
Yakut Republican Oncology Dispensary; M.K. Ammosov North-Eastern Federal University
Autor responsável pela correspondência
Email: feodossiaiv@inbox.ru
ORCID ID: 0000-0001-7661-1279
Cand. Sci. (Med.)., Head of the Department of Drug Treatment, Associate Professor at the Basic Department of Oncology
Rússia, Yakutsk; YakutskT. Nikolaeva
Yakut Republican Oncology Dispensary
Email: feodossiaiv@inbox.ru
ORCID ID: 0000-0002-1099-573X
Rússia, Yakutsk
N. Spiridonova
Yakut Republican Oncology Dispensary
Email: feodossiaiv@inbox.ru
ORCID ID: 0009-0001-0960-6522
Rússia, Yakutsk
L. Afanasyeva
M.K. Ammosov North-Eastern Federal University
Email: feodossiaiv@inbox.ru
ORCID ID: 0000-0003-2592-5125
Rússia, Yakutsk
P. Nikiforov
M.K. Ammosov North-Eastern Federal University; Yakut Republican Medical Information and Analytical Center
Email: feodossiaiv@inbox.ru
ORCID ID: 0000-0002-2758-155X
Rússia, Yakutsk; Yakutsk
T. Zharnikova
Yakut Republican Oncology Dispensary; M.K. Ammosov North-Eastern Federal University
Email: feodossiaiv@inbox.ru
ORCID ID: 0000-0002-7967-3704
Rússia, Yakutsk; Yakutsk
Bibliografia
- Globocan cancer observatory, 2020. https://gco.iarc.fr.
- Косенок В. К., Бельская Л. В., Массард Жильбер, Завьялов А. А. Статистические особенности заболеваемости раком легкого в омской области. Сибирский онкологический журнал. 2016;15(4):21–5. [Kosenok V.K., Belskaya L.V., Massard Gilbert, Zavyalov A.A. Statistical features of the incidence of lung cancer in the Omsk region. Sibirskiy onkologicheskiy zhurnal. 2016;15(4):21–5. (In Russ.)].
- Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.) Состояние онкологической помощи населению России в 2022 г. М., 2022. 239 с. Kaprin A.D., Starinsky V.V., Shakhzado-va A.O. (ed.) The state of oncological care for the population of Russia in 2022. M., 2022. 239 p. [(In Russ.)]. URL: https://glavonco.ru/cancer_register/sop-2022-v2.pdf.
- Лактионов К.К., Артамонова Е.В., Бредер В.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023;13(#3s2):42–65. [Laktionov K.K., Artamonova E.V., Breder V.V. et al. Practical recommendations for drug treatment of non-small cell lung cancer. Practical recommendations RUSSCO, part 1. Malignant tumors. 2023;13(#3s2):42–65. (In Russ.)]. doi: 10.18027/2224-5057-2023-133s2-1-42-65.
- National Comprehensive Cancer Network. Clinical Practice guidelines in oncology: non-small cell lung cancer, version 5.2023. URL: https://www.nccn.org/guidelines/category_1. Accessed November 21, 2023.
- Socinski M.A., Jotte R.M., Cappuzzo F., et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301.
- Reck M., Mok T.S.K., Nishio M., et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet. Respir Med. 2019;7(5):387–401. doi: 10.1016/S2213-2600(19)30084-0.
- Socinski M.A., Nishio M., Jotte R.M., et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909–24. doi: 10.1016/j.jtho.2021.07.009.
- Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi: 10.1016/j.immuni.2013.07.012.
- Бредер В.В., Базин И.С., Балахнин П.В. и др. Практические рекомендации по лекарственному лечению больных злокачественными опухолями печени и желчевыводящей системы. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023;13(#3s2):494–538. [Breder V.V., Bazin I.S., Balakhnin P.V. et al. Practical recommendations for drug treatment of patients with malignant tumors of the liver and biliary system. Practical recommendations RUSSCO, part 1. Malignant tumors. 2023;13(#3s2):494–538. (In Russ.)]. doi: 10.18027/2224-5057-2023-13-3s2-1-494-538.
- Волкова М.И., Носов Д.А., Алексеев Б.Я. и др. Практические рекомендации по лекарственному лечению почечноклеточного рака. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023;13(#3s2):609–19. [Volkova M.I., Nosov D.A., Alekseev B.Ya. et al. Practical recommendations for drug treatment of renal cell cancer. Practical recommendations RUSSCO, part 1. Malignant tumors. 2023;13(#3s2):609–19. (In Russ.)]. doi: 10.18027/2224-5057-2023-13-3s2-1-609-619.
- Нечушкина В.М., Коломиец Л.А., Кравец О.А. и др. Практические рекомендации по лекарственному лечению рака тела матки и сарком матки. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023;13(#3s2):263–79. [Nechushkina V.M., Kolomiets L.A., Kravets O.A. et al. Practical recommendations for drug treatment of uterine cancer and uterine sarcomas. Practical recommendations RUSSCO, part 1. Malignant tumors. 2023;13(#3s2):263–79. (In Russ.)]. doi: 10.18027/2224-5057-2023-13-3s2-1-263-279.
Arquivos suplementares
![](/img/style/loading.gif)